Cancer-Drug Spending in U.S. May Climb 42 Percent by 2013
This article is for subscribers only.
Spending on cancer drugs by U.S. employers and health insurers may climb as much as 42 percent by the end of 2013 as the number of patients rises and new medicines reach the market, Medco Health Solutions Inc. said.
Specialty drugs that are among the costliest cancer medicines and that lack generic equivalents will drive most of the spending increases, Franklin Lakes, New-Jersey based Medco, the largest pharmacy benefits manager by revenue, said today in a report.